Multilayered nanoparticle and methods of manufacturing and using the same

1. A multilayered nanoparticle for delivery of RNA to a cell, the nanoparticle comprising: a core nanoparticle coated by alternating positively and negatively charged polymer layers, wherein the number of layers is 2 or more and wherein at least one of the negatively charged polymer layers comprises RNA; wherein the RNA is an siRNA having a nucleotide sense sequence as set forth in SEQ ID NO:1 and a nucleotide antisense sequence set forth in SEQ ID NO:2.

2. The multilayered nanoparticle according to claim 1 , wherein the negatively charged polymer layer comprises siRNA or each of the negatively charged polymer layer comprises siRNA and is sandwiched between two positively charged polymer layers.

3. The multilayered nanoparticle according to claim 1 , wherein the positively charged polymer is a polycation or comprises poly (L-arginine).

4. The multilayered nanoparticle according to claim 1 , wherein the negatively charged polymer is a polyanion or comprises dextran sulphate.

5. The multilayered nanoparticle according to claim 1 , further comprising a targeting peptide or targeting protein as an outermost layer.

6. The multilayered nanoparticle according to claim 1 , wherein the nanoparticle core is biocompatible or biodegradable.

7. The multilayered nanoparticle according to claim 1 , wherein the nanoparticle core comprises hydroxyapatite, calcium carbonate, silica, poly(lactic acid) (PLA), or combinations thereof.

8. The multilayered nanoparticle according to claim 1 , wherein the nanoparticle core comprises a liposome.

9. The multilayered nanoparticle according to claim 1 , wherein the nanoparticle core is negatively charged.

10. The multilayered nanoparticle according to claim 1 , wherein the multilayered nanoparticle comprises 3 to 10 layers.

11. The multilayered nanoparticle according to claim 1 , wherein an outermost layer comprises poly(L-arginine).

12. The multilayered nanoparticle according to claim 1 , wherein the multilayer comprises at least 2 negatively charged polymer layers comprising siRNA.

13. The multilayered nanoparticle according to claim 1 , wherein the siRNA targets a Secreted Protein, Acidic and Rich in Cysteine (SPARC) gene.

14. A method for manufacturing a multilayered nanoparticle comprising a core nanoparticle coated by alternating positively and negatively charged polymer layers, wherein the number of layers is 2 or more and wherein at least one of the negatively charged polymer layers comprises RNA, wherein the RNA is an siRNA having a nucleotide sense sequence as set forth in SEQ ID NO:1 and a nucleotide antisense sequence set forth in SEQ ID NO:2,

the method comprising the steps of:

a. Providing a nanoparticle core;

b. Contacting the nanoparticle core with a positively charged or negatively charged polymer to form a first polymer layer on the nanoparticle core;

c. Contacting the coated nanoparticle of step b) with a polymer charged opposite to that used in step b) to form a second polymer layer on the nanoparticle;

d. Optionally repeating steps b) and c).

15. A method for delivering RNA to a cell or organism, the method comprising: contacting said cell or organism with an effective amount of a multilayered nanoparticle comprising a core nanoparticle coated by alternating positively and negatively charged polymer layers, wherein the number of layers is 2 or more and wherein at least one of the negatively charged polymer layers comprises RNA, wherein the RNA is an siRNA having a nucleotide sense sequence as set forth in SEQ ID NO:1 and a nucleotide antisense sequence set forth in SEQ ID NO:2.

16. A method for treating an RNA-treatable disease or disorder in a subject, the method comprising administering to the subject an effective amount of a multilayered nanoparticle comprising a core nanoparticle coated by alternating positively and negatively charged polymer layers, wherein the number of layers is 2 or more and wherein at least one of the negatively charged polymer layers comprises RNA, wherein the RNA is an siRNA having a nucleotide sense sequence as set forth in SEQ ID NO:1 and a nucleotide antisense sequence set forth in SEQ ID NO:2.

17. The method according to claim 16 , wherein the siRNA inhibits Secreted Protein, Acidic and Rich in Cysteine (SPARC) expression and the RNA-treatable disease or disorder is scarring and said treatment reduces scarring in the subject.

18. The method according to claim 17 , wherein the multilayered nanoparticle is administered to the conjunctiva after eye surgery.